{"id":461,"date":"2025-02-18T04:58:00","date_gmt":"2025-02-18T04:58:00","guid":{"rendered":"https:\/\/cancertreatment.org.uk\/?post_type=members&#038;p=461"},"modified":"2025-03-24T09:35:25","modified_gmt":"2025-03-24T09:35:25","slug":"gordon-rustin","status":"publish","type":"members","link":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/","title":{"rendered":"Professor Gordon Rustin (Founder)"},"content":{"rendered":"\n<p>Joined in 1985.<\/p>\n\n\n\n<p>Professor Gordon Rustin qualified from the Middlesex Hospital, London in 1971. He was appointed Senior Lecturer in Medical Oncology at the Charing Cross Hospital in 1984 but moved full-time to Mount Vernon Hospital to become Director of Medical Oncology in 1995, where he was leading research and clinical trial of vascular disruptive agents. Professor Rustin is widely published, with over 320 papers to his name on the management of gynaecological cancers, germ cell tumours, the use of tumour markers, and on phase I, II, and III trials. He was awarded an honorary professorship in 2001 by UCL, later becoming the professor of cancer therapy at the Institute of Cancer Research.<\/p>\n\n\n\n<p>He retired from the hospital in 2018 but continues his private practice at BMI Bishops Wood Hospital as well as medico-legal work, refereeing papers and lecturing.<\/p>\n","protected":false},"featured_media":431,"template":"","members_category":[8],"class_list":["post-461","members","type-members","status-publish","has-post-thumbnail","hentry","members_category-trustees"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust<\/title>\n<meta name=\"description\" content=\"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust\" \/>\n<meta property=\"og:description\" content=\"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/\" \/>\n<meta property=\"og:site_name\" content=\"The Cancer Treatment and Research Trust\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ctrtrust\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T09:35:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ctrtrust\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/\",\"url\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/\",\"name\":\"Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust\",\"isPartOf\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp\",\"datePublished\":\"2025-02-18T04:58:00+00:00\",\"dateModified\":\"2025-03-24T09:35:25+00:00\",\"description\":\"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.\",\"breadcrumb\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage\",\"url\":\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp\",\"contentUrl\":\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp\",\"width\":400,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cancertreatment.org.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Professor Gordon Rustin (Founder)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cancertreatment.org.uk\/#website\",\"url\":\"https:\/\/cancertreatment.org.uk\/\",\"name\":\"The Cancer Treatment and Research Trust\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/#organization\"},\"alternateName\":\"CTRT\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cancertreatment.org.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cancertreatment.org.uk\/#organization\",\"name\":\"The Cancer Treatment and Research Trust\",\"alternateName\":\"CTRT\",\"url\":\"https:\/\/cancertreatment.org.uk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cancertreatment.org.uk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/02\/CTRT-logo.svg\",\"contentUrl\":\"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/02\/CTRT-logo.svg\",\"caption\":\"The Cancer Treatment and Research Trust\"},\"image\":{\"@id\":\"https:\/\/cancertreatment.org.uk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ctrtrust\",\"https:\/\/x.com\/ctrtrust\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust","description":"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/","og_locale":"en_US","og_type":"article","og_title":"Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust","og_description":"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.","og_url":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/","og_site_name":"The Cancer Treatment and Research Trust","article_publisher":"https:\/\/www.facebook.com\/ctrtrust","article_modified_time":"2025-03-24T09:35:25+00:00","og_image":[{"width":400,"height":400,"url":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_site":"@ctrtrust","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/","url":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/","name":"Professor Gordon Rustin (Founder) - The Cancer Treatment and Research Trust","isPartOf":{"@id":"https:\/\/cancertreatment.org.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage"},"image":{"@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage"},"thumbnailUrl":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp","datePublished":"2025-02-18T04:58:00+00:00","dateModified":"2025-03-24T09:35:25+00:00","description":"Professor Rustin specialises in gynae and testicular cancer. He is also involved in the drug development of Vascular disruptive agents.","breadcrumb":{"@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#primaryimage","url":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp","contentUrl":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/03\/Gordon-circle-200x200@2x.webp","width":400,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/cancertreatment.org.uk\/members\/gordon-rustin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cancertreatment.org.uk\/"},{"@type":"ListItem","position":2,"name":"Professor Gordon Rustin (Founder)"}]},{"@type":"WebSite","@id":"https:\/\/cancertreatment.org.uk\/#website","url":"https:\/\/cancertreatment.org.uk\/","name":"The Cancer Treatment and Research Trust","description":"","publisher":{"@id":"https:\/\/cancertreatment.org.uk\/#organization"},"alternateName":"CTRT","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cancertreatment.org.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cancertreatment.org.uk\/#organization","name":"The Cancer Treatment and Research Trust","alternateName":"CTRT","url":"https:\/\/cancertreatment.org.uk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancertreatment.org.uk\/#\/schema\/logo\/image\/","url":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/02\/CTRT-logo.svg","contentUrl":"https:\/\/cancertreatment.org.uk\/wp-content\/uploads\/2025\/02\/CTRT-logo.svg","caption":"The Cancer Treatment and Research Trust"},"image":{"@id":"https:\/\/cancertreatment.org.uk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ctrtrust","https:\/\/x.com\/ctrtrust"]}]}},"_links":{"self":[{"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/members\/461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/members"}],"about":[{"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/types\/members"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/media\/431"}],"wp:attachment":[{"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/media?parent=461"}],"wp:term":[{"taxonomy":"members_category","embeddable":true,"href":"https:\/\/cancertreatment.org.uk\/wp-json\/wp\/v2\/members_category?post=461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}